{"id":482199,"date":"2020-05-04T07:56:01","date_gmt":"2020-05-04T07:56:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=482199"},"modified":"2020-05-04T07:56:01","modified_gmt":"2020-05-04T07:56:01","slug":"blastic-plasmacytoid-dendritic-cell-neoplasm-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/blastic-plasmacytoid-dendritic-cell-neoplasm-market-insights-epidemiology-and-market-forecast2030_482199.html","title":{"rendered":"Blastic Plasmacytoid Dendritic Cell Neoplasm Market Insights, Epidemiology and Market Forecast-2030"},"content":{"rendered":"
\"Blastic<\/a><\/p>\n
\n
DelveInsight<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy, historical and forecasted epidemiology as well as the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

 <\/span>Blastic Plasmacytoid Dendritic Cell Neoplasm Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

(Albany, US) <\/span>DelveInsight launched a new report on Blastic Plasmacytoid Dendritic Cell Neoplasm Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

Some of the key facts of the report<\/span>
1. BPDCN comprise of less than 1% of all hematologic malignancies, that results around 1,000 to 1,400 cases prevailing annually in the US and Europe when combined.<\/span>
2. 90% of BPDCN patients with present asymptomatic skin lesions and early identification can be difficult due to overlapping features along with other benign and malignant disorders.<\/span><\/p>\n

Key benefits of the report<\/span>
1. Blastic Plasmacytoid Dendritic Cell Neoplasm market report covers a descriptive overview and comprehensive insight of the BPDCN epidemiology and Blastic Plasmacytoid Dendritic Cell Neoplasm market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span>
2. BPDCN market report provides insights on the current and emerging therapies.<\/span>
3. Blastic Plasmacytoid Dendritic Cell Neoplasm market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. BPDCN market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Blastic Plasmacytoid Dendritic Cell Neoplasm market.<\/span><\/p>\n

Request for sample pages<\/a><\/p>\n

\"\"<\/a><\/p>\n

“Men are often diagnosed with BPDCN than women (around 3:1 ratio), and it is most prevalent in the patient’s age 60 years and older.”<\/span><\/p>\n

While there is a high initial response rate with standard chemotherapeutic regimens for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the responses are typically not durable, and this remains a very aggressive disease with generally poor outcomes. For this reason, the standard approach for eligible patients has been high-dose induction chemotherapy, preferably with acute lymphoblastic leukaemia (ALL)- based regimens followed by consolidation with allogeneic hematopoietic stem cell transplantation (alloHSCT). Unfortunately, many patients with this disease are elderly and frail and cannot tolerate this therapy, and the low-dose regimens being used in this population are generally not as effective.<\/span><\/p>\n

The current studies suggest that treatment with high-dose chemotherapy, followed by allogeneic HSCT in CR1 may result in improved overall survival for BPDCN.<\/span><\/p>\n

There is currently only one approved therapy or established standard of care for BPDCN due to its rarity and the lack of prospective clinical trials. Elzonris (tagraxofusp-erzs, Stemline Therapeutics), is the only approved therapy for the treatment of BPDCN. Elzonris is given for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and pediatric patients two years and older.<\/span><\/p>\n

The factors that shall further expedite the growth of Blastic Plasmacytoid Dendritic Cell Neoplasm market during the forecast period of (2020–2030) include high incidence, increased morbidity rate due to Blastic Plasmacytoid Dendritic Cell Neoplasm and increasing awareness about available treatments.<\/span><\/p>\n

The launch of the emerging therapies is expected to significantly impact Blastic Plasmacytoid Dendritic Cell Neoplasm treatment scenario in the upcoming years:-<\/span>
Drugs covered<\/span>
1. IMGN632<\/span>
2. UCART123<\/span>
3. XmAb14045<\/span>
4. MB 102<\/span>
And many others<\/span><\/p>\n

The key players in BPDCN market are:<\/span>
1. Immunogen<\/span>
2. Cellectis<\/span>
3. Xencor<\/span>
4. MustangBio<\/span><\/p>\n

And many others<\/span><\/p>\n

Table of contents<\/span>
1. Report Introduction<\/span>
2. Blastic Plasmacytoid Dendritic Cell Neoplasm Market Share at a glance<\/span>
3. Blastic Plasmacytoid Dendritic Cell Neoplasm Disease Background and Overview<\/span>
4. BPDCN Epidemiology and Patient Population<\/span>
5. Country Wise Blastic Plasmacytoid Dendritic Cell Neoplasm Epidemiology<\/span>
5.1. United States<\/span>
5.2. EU5<\/span>
5.2.1. Germany<\/span>
5.2.2. France<\/span>
5.2.3. Italy<\/span>
5.2.4. Spain<\/span>
5.2.5. United Kingdom<\/span>
5.3. Japan<\/span>
6. Blastic Plasmacytoid Dendritic Cell Neoplasm Current Treatment & Medical Practices<\/span>
7. Blastic Plasmacytoid Dendritic Cell Neoplasm Marketed Drugs<\/span>
8. Elzonris (Tagraxofusp-erzs): Stemline Therapeutics<\/span>
9. Current Unmet Needs of Blastic Plasmacytoid Dendritic Cell Neoplasm<\/span>
10. Blastic Plasmacytoid Dendritic Cell Neoplasm Emerging Therapeutics<\/span>
10.1.Key Cross Competition<\/span>
10.2.IMGN632: Immunogen<\/span>
10.3.UCART123: Cellectis<\/span>
10.4.XmAb14045: Xencor<\/span>
10.5.MB 102: MustangBio<\/span>
11. BPDCN Market Size<\/span>
12. Region-Wise Blastic Plasmacytoid Dendritic Cell Neoplasm Market size<\/span>
12.2. EU-5<\/span>
12.2.1. Germany<\/span>
12.2.2. France<\/span>
12.2.3. Italy<\/span>
12.2.4. Spain<\/span>
12.2.5. United Kingdom<\/span>
12.3. Japan<\/span>
13. Market Drivers<\/span>
14. Market Barriers<\/span>
15. Appendix<\/span>
16. Blastic Plasmacytoid Dendritic Cell Neoplasm Report Methodology<\/span>
17. DelveInsight Capabilities<\/span>
18. Disclaimer<\/span>
19. About DelveInsight<\/span><\/p>\n

About DelveInsight<\/span>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight DelveInsight’s “Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy, historical and forecasted epidemiology as well as the Blastic plasmacytoid dendritic … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-482199","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/482199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=482199"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/482199\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=482199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=482199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=482199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}